Literature DB >> 15306245

Influence of moderate and profound hyperventilation on cerebral blood flow, oxygenation and metabolism.

Tobias Clausen1, Alexander Scharf, Matthias Menzel, Jens Soukup, Carsten Holz, Andreas Rieger, Frank Hanisch, Endre Brath, Norbert Nemeth, Iren Miko, Peter Vajkoczy, Joachim Radke, Dirk Henze.   

Abstract

OBJECTIVE: The aim of the present study was to examine the impact of moderate and profound hyperventilation on regional cerebral blood flow (rCBF), oxygenation and metabolism.
MATERIALS AND METHODS: Twelve anesthetized pigs were subjected to moderate (mHV) and profound (pHV) hyperventilation (target arterial pO(2): 30 and 20 mmHg, respectively) for 30 min each, after baseline normoventilation (BL) for 1 h. Local cerebral extracellular fluid (ECF) concentrations of glucose, lactate, pyruvate and glutamate as well as brain tissue oxygenation (p(ti)O(2)) were monitored using microdialysis and a Licox oxygen sensor, respectively. In nine pigs, regional cerebral blood flow (rCBF) was also continuously measured via a thermal diffusion system.
RESULTS: Both moderate and profound hyperventilation resulted in a significant decrease in rCBF (BL: 37.9+/-4.3 ml/100 g/min; mHV: 29.4+/-3.6 ml/100 g/min; pHV: 23.6+/-4.7 ml/100 g/min; p<0.05) and p(ti)O(2) (BL: 22.7+/-4.1 mmHg; mHV: 18.9+/-4.9 mmHg; pHV: 13.0+/-2.2 mmHg; p<0.05). A p(ti)O(2) decrease below the critical threshold of 10 mmHg was induced in three animals by moderate hyperventilation and in five animals by profound hyperventilation. Furthermore, significant increases in lactate (BL: 1.06+/-0.18 mmol/l; mHV: 1.36+/-0.20 mmol/l; pHV: 1.67+/-0.17 mmol/l; p<0.005), pyruvate (BL: 46.4+/-7.8 micromol/l; mHV: 58.0+/-10.3 micromol/l; pHV: 66.1+/-12.7 micromol/l; p<0.05), and lactate/glucose ratio were observed during hyperventilation. (Data are presented as mean+/-S.E.M.)
CONCLUSIONS: Both moderate and profound hyperventilation may result in insufficient regional oxygen supply and anaerobic metabolism, even in the uninjured brain. Therefore, the use of hyperventilation cannot be considered as a safe procedure and should either be avoided or used with extreme caution.

Entities:  

Mesh:

Year:  2004        PMID: 15306245     DOI: 10.1016/j.brainres.2004.05.099

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Direct cerebral oxygenation monitoring--a systematic review of recent publications.

Authors:  Erhard W Lang; Jamin M Mulvey; Yugan Mudaliar; Nicholas W C Dorsch
Journal:  Neurosurg Rev       Date:  2007-01-13       Impact factor: 3.042

2.  The use of hyperventilation therapy after traumatic brain injury in Europe: an analysis of the BrainIT database.

Authors:  J-O Neumann; I R Chambers; G Citerio; P Enblad; B A Gregson; T Howells; J Mattern; P Nilsson; I Piper; A Ragauskas; J Sahuquillo; Y H Yau; K Kiening
Journal:  Intensive Care Med       Date:  2008-05-01       Impact factor: 17.440

3.  The anesthetic effects on vasopressor modulation of cerebral blood flow in an immature swine model.

Authors:  Benjamin Bruins; Todd J Kilbaugh; Susan S Margulies; Stuart H Friess
Journal:  Anesth Analg       Date:  2013-03-04       Impact factor: 5.108

4.  Differing effects when using phenylephrine and norepinephrine to augment cerebral blood flow after traumatic brain injury in the immature brain.

Authors:  Stuart H Friess; Benjamin Bruins; Todd J Kilbaugh; Colin Smith; Susan S Margulies
Journal:  J Neurotrauma       Date:  2014-11-24       Impact factor: 5.269

5.  Studying cerebral hemodynamics and metabolism using simultaneous near-infrared spectroscopy and transcranial Doppler ultrasound: a hyperventilation and caffeine study.

Authors:  Runze Yang; Julien Brugniaux; Harinder Dhaliwal; Andrew E Beaudin; Misha Eliasziw; Marc J Poulin; Jeff F Dunn
Journal:  Physiol Rep       Date:  2015-04

6.  Assessment of Visual and Brainstem Auditory Evoked Potentials in Patients with Hashimoto's Thyroiditis.

Authors:  Marta Waliszewska-Prosół; Maria Ejma
Journal:  J Immunol Res       Date:  2021-03-03       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.